Synthetech Acquires Peptide Resin Technology From Colorado
News Jan 16, 2006
Synthetech, Inc. has acquired the technology assets and customer lists of Colorado Biotechnology Associates, Incorporated (CBA) for a range of cross-linked and functionalized polymeric resins used widely in Solid Phase Peptide Synthesis (SPPS).
Under the arrangement, Dr. Rodger Raubach, CBA's founder and principal owner, will transfer proprietary resin know-how to Synthetech, and serve as a consultant for scale-up, technical support, customer qualification and business development for a period of three years.
The transferred technology includes the procedure to attach the specified terminal amino acid to the resin, a key value-added service to peptide customers.
Synthetech plans to produce and have available for distribution resin batches within the next three months.
Commenting on the transaction, M. "Sreeni" Sreenivasan, Synthetech's President & CEO, said, "SPPS resins represent a product line that is complementary to our established line of peptide building blocks, with a distinct overlap in the customer base."
"Dr. Raubach has developed unique know- how and an enviable reputation in the field of SPPS resins over the past couple of decades. We look forward to working with Dr. Raubach and firmly establishing Synthetech as a world class supplier of high quality resins."
"We believe that with Dr. Raubach's assistance, Synthetech is well positioned to rapidly enter this market."
Dr. Raubach added, "With my desire to retire and wind up CBA, I believe there is no better choice to carry on the work I began in the resin field than Synthetech."
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE